ADGI
Income statement / Annual
Last year (2021), Adagio Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2021, Adagio Therapeutics, Inc.'s net income was -$226.79 M.
See Adagio Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2021
|
Period Ended |
12/31/2021 |
Operating Revenue |
$0.00 |
Cost of Revenue |
$0.00
|
Gross Profit |
$0.00
|
Gross Profit Ratio |
0
|
Research and Development Expenses |
$182.89 M
|
General & Administrative Expenses |
$0.00
|
Selling & Marketing Expenses |
$0.00
|
Selling, General & Administrative Expenses |
$36.52 M
|
Other Expenses |
$7.50 M
|
Operating Expenses |
$226.91 M
|
Cost And Expenses |
$226.91 M
|
Interest Income |
$0.00
|
Interest Expense |
$0.00
|
Depreciation & Amortization |
$1.43 M
|
EBITDA |
-$225.36 M |
EBITDA Ratio |
0
|
Operating Income Ratio |
0
|
Total Other Income/Expenses Net |
$118,000.00
|
Income Before Tax |
-$226.79 M
|
Income Before Tax Ratio |
0
|
Income Tax Expense |
$118,000.00
|
Net Income |
-$226.79 M
|
Net Income Ratio |
0
|
EPS |
-2.04 |
EPS Diluted |
-2.04 |
Weighted Average Shares Out |
$111.25 M
|
Weighted Average Shares Out Diluted |
$111.25 M
|
Link |
|